What is Amedisys, Inc.'s TTM Return on Invested Capital (ROIC)?

Amedisys, Inc. (AMED) reported 10.5% TTM ROIC in FY2024 normalized.

What is Amedisys, Inc.'s DCF fair value?

Amedisys, Inc. (AMED) base-case DCF fair value: $124.25 per share.

What is Amedisys, Inc.'s economic moat?

Amedisys, Inc. has a Narrow economic moat. Operational scale, MA payer contracts, and Star ratings provide modest but durable advantages limited by single-payer concentration and labor dependency.

What is the bull case for Amedisys, Inc.?

Amedisys, Inc. bull case: CMS rate environment normalizes and operating margin recovers to FY2021 peak (~11.5%); FCF compounds at >10% of revenue; standalone DCF supports ~$155/share.

What is the bear case for Amedisys, Inc.?

Amedisys, Inc. bear case: PDGM behavioral cut intensifies to permanent −4% rate impact; combined with sustained 5%+ clinical labor wage inflation, operating margin compresses to 6.5%; standalone DCF supports only ~$66/share.

What are the top catalysts for Amedisys, Inc.?

Top catalysts: UNH topping bid at $101.00 cash (May 2023)—bull thesis crystallized; immediate re-rating; DOJ Second Request resolution via ~130 care-center divestitures (2023-2024)—deal closure path cleared; Shareholder approval and final regulatory clearances (2023-2025)—regulatory path secured.

What are the top risks to Amedisys, Inc.?

Top risks: CMS PDGM behavioral cut (−2.89% permanent rate impact, FY2024)—materialized; margin pressure absorbed; Clinical labor wage inflation peaked at 5-8% in 2022-2023—materialized; margin compression validated; OPCH termination fee ($106M paid, FY2023 GAAP hit)—materialized; one-time P&L impact.

What is Amedisys, Inc.'s operating margin?

Amedisys, Inc. (AMED) reports 4% operating margin (FY2024). Gross margin 26.7%.

What is Amedisys, Inc.'s net debt?

Amedisys, Inc. (AMED) carries net debt of $26M as of Q2 2025.

Who are Amedisys, Inc.'s main competitors?

Amedisys, Inc. (AMED) directly competes with Enhabit (EHAB), Pennant Group (PNTG), Addus HomeCare (ADUS).

How does Amedisys, Inc. make money?

Amedisys, Inc. (AMED)'s top revenue segments: Home Health (70%), Hospice (25%), High Acuity Care (Contessa) (2%) (FY2024).

Margin of Insight

← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Amedisys, Inc.

AMED

NEUTRAL

May 28, 2026

Research Conclusion

Status: CLOSED. Amedisys ceased to be an investable public security on August 14, 2025, when UnitedHealth Group/Optum closed its all-cash acquisition at $101.00/share ($3.3B equity / ~$3.35B enterprise value). The realized deal price landed essentially at the probability-weighted standalone fair value (~$108)—fair, not premium. Public-market shareholders received full standalone economic value; the strategic-acquirer premium was retained by the buyer. No forward thesis on the AMED security exists.

Company Overview & Moat Assessment

Amedisys was a Baton Rouge, Louisiana-headquartered post-acute and in-home healthcare services provider operating three segments: Home Health (~70% revenue; ~340 care centers in 36 states), Hospice (~25% revenue; ~165 hospice care centers in 33 states), and High Acuity Care (~5% revenue; Contessa Health hospital-at-home model). Revenue scaled from $1.50B (FY2017) to $2.35B (FY2024)—a 6.6% CAGR driven primarily by hospice rollups and the 2021 Contessa acquisition. The business model was Medicare-dependent (~75-80%), capital-light (CapEx ~0.3% of revenue), and operationally moated by scale-density economics, MA payer relationships, and CMS Star Ratings.

▲ Bull Case

◆CMS rate environment normalizes and operating margin recovers to FY2021 peak (~11.5%); FCF compounds at >10% of revenue; standalone DCF supports ~$155/share.
◆High Acuity Care (Contessa) inflects to profitability by FY2027, adding $150-200M revenue at break-even; segment optionality unlocks $10-15/share.
◆Hospice ADC growth accelerates with post-pandemic demographic tailwind, reaching ~14,500 ADC by FY2027 (vs ~12,800 at FY2024); pricing + mix drives 4.8%/yr revenue growth.

▼ Bear Case

◆PDGM behavioral cut intensifies to permanent −4% rate impact; combined with sustained 5%+ clinical labor wage inflation, operating margin compresses to 6.5%; standalone DCF supports only ~$66/share.
◆GIP audit recurrence triggers $50-100M revenue restatement; Contessa Health is impaired further with $100M+ goodwill write-down.
◆Major MA payer contract losses in top-20 metros validate structural buyer-power thesis; revenue growth stalls at 1.5%/yr.

Primary Debate on Wall Street

“The dominant pre-deal debate was standalone DCF vs. strategic-takeover option value. Bears anchored on standalone DCF in the $60-90 range (PDGM cuts + labor inflation → compressed margin → low-single-digit revenue growth); defensible math but wrong frame. Bulls anchored on takeover-option value with reference to Kindred/Humana and LHC/Optum precedent multiples; correct frame for the actual investing decision. Deal closed at $101 in August 2025; probability-weighted standalone fair value was $108. Both sides partially right—bull frame correctly identified the takeover catalyst; bear frame correctly identified that the price would not be a bull-case strategic premium.”

Top Catalysts

◆UNH topping bid at $101.00 cash (May 2023)—bull thesis crystallized; immediate re-rating
◆DOJ Second Request resolution via ~130 care-center divestitures (2023-2024)—deal closure path cleared
◆Shareholder approval and final regulatory clearances (2023-2025)—regulatory path secured
◆Deal close at $101.00 per share in cash (August 14, 2025)—realized outcome at fair-value parity

Top Risks

◆CMS PDGM behavioral cut (−2.89% permanent rate impact, FY2024)—materialized; margin pressure absorbed
◆Clinical labor wage inflation peaked at 5-8% in 2022-2023—materialized; margin compression validated
◆OPCH termination fee ($106M paid, FY2023 GAAP hit)—materialized; one-time P&L impact
◆DOJ deal-block risk via antitrust second request—did not materialize; divestitures resolved concerns
◆Major GIP audit recurrence with revenue restatement—did not materialize; no post-2021 major restatement
◆Cyberattack disruption (Change Healthcare 2024 incident affected industry)—sector risk, not AMED-specific

Full Memo Continues

5 more sections, locked

●
Valuation Range & DCF
Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
●
Risk/Reward Assessment
Position-sizing framework with explicit upside/downside skew and entry conditions.
●
Management & Capital Allocation
Multi-year capital-allocation track record, incentive alignment, and management readout.
●
Monitoring Framework
What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
●
Unresolved Questions
Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/AMED/memo
Authorization: Bearer spt_...

How agents access →← Free primer

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.